High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease

Blood
Sigbjørn BerentsenGeir E Tjønnfjord

Abstract

Most patients diagnosed with primary chronic cold agglutinin disease (CAD) have a clonal lymphoproliferative bone marrow disorder. Treatment with rituximab is the only well-documented effective therapy, leading to 45%-60% partial responses (PR). Complete responses (CR) are rare, and median response duration is only 11 months. In a prospective multicenter trial, 29 patients received rituximab 375 mg/m(2) on days 1, 29, 57 and 85; and fludarabine orally, 40 mg/m(2) on days 1-5, 29-34, 57-61 and 85-89. Twenty-two patients (76%) responded, 6 (21%) achieving CR and 16 (55%) PR. Among 10 patients nonresponsive to rituximab monotherapy, 1 achieved CR and 6 PR. Median increase in hemoglobin level was 3.1 g/dL among the responders and 4.0 g/dL in those who achieved CR. Lower quartile of response duration was not reached after 33 months. Estimated median response duration was more than 66 months. Grade 3-4 hematologic toxicity occurred in 12 patients (41%). In conclusion, fludarabine and rituximab combination therapy is very efficient in patients with CAD. Toxicity may be a concern, and benefits should be carefully weighed against risks in very old and comorbid patients. It remains to be established whether the combination should be firs...Continue Reading

References

Jan 1, 1965·Scandinavian Journal of Haematology·M HarboeR S Evans
Oct 1, 1994·European Journal of Haematology·H F Hillen, S J Bakker
Dec 1, 1996·American Journal of Hematology·A Jacobs
May 1, 1997·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·S BerentsenE Ulvestad
Mar 21, 1998·European Journal of Haematology·E Ulvestad
Oct 26, 1999·European Journal of Haematology·E UlvestadF V Shammas
Jul 29, 2000·European Journal of Haematology·S BerentsenE Ulvestad
May 2, 2001·Nature Reviews. Genetics·J SmeitinkS DiMauro
Jul 6, 2001·Scandinavian Journal of Immunology·E UlvestadT E Mollnes
Apr 30, 2003·Seminars in Oncology·Véronique Leblond, Sylvain Choquet
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanS H Bernstein
Dec 3, 2005·Leukemia & Lymphoma·Claudia SchöllkopfHenrik Birgens
Nov 25, 2006·Hematology·Morie A Gertz
Nov 28, 2006·Frontiers in Bioscience : a Journal and Virtual Library·Gregg J Silverman
Sep 28, 2007·Cardiovascular & Hematological Disorders Drug Targets·Sigbjørn BerentsenGeir E Tjønnfjord
Dec 7, 2007·Haematologica·Sigbjørn Berentsen
Jul 1, 2008·Current Opinion in Immunology·Ronald P Taylor, Margaret A Lindorfer
Apr 14, 2009·Clinical Lymphoma & Myeloma·Sigbjørn Berentsen

❮ Previous
Next ❯

Citations

May 22, 2013·Archivum Immunologiae Et Therapiae Experimentalis·José Carlos Jaime-PérezDavid Gómez-Almaguer
Nov 20, 2010·Annals of Hematology·Daan DierickxAndré Delannoy
Sep 8, 2015·Expert Review of Hematology·Wilma Barcellini
Jun 19, 2012·The Medical Clinics of North America·Daan DierickxAndré Delannoy
Feb 15, 2012·Blood Reviews·Sigbjørn Berentsen, Geir E Tjønnfjord
Apr 9, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·D Rigal, F Meyer
Nov 20, 2015·Blood·Robert A Brodsky
Mar 10, 2011·British Journal of Haematology·Sigbjørn Berentsen
May 9, 2013·British Journal of Haematology·Anita D'SouzaMorie A Gertz
Feb 18, 2011·American Journal of Hematology·Daan DierickxDrew Provan
Feb 18, 2014·British Journal of Haematology·Roger G OwenUNKNOWN British Committee for Standards in Haematology
Feb 18, 2014·American Journal of Hematology·Antoine NéelMohamed Hamidou
Sep 26, 2015·Seminars in Hematology·Wilma Barcellini
Aug 21, 2014·British Journal of Clinical Pharmacology·Chaturaka RodrigoLallindra Gooneratne
Jun 5, 2015·Hematology/oncology Clinics of North America·Sigbjørn BerentsenGeir E Tjønnfjord
Apr 2, 2011·Clinical Lymphoma, Myeloma & Leukemia·Marvin J Stone
Apr 29, 2015·Case Reports in Hematology·Shinsaku ImashukuKatsuyasu Saigo
Feb 24, 2015·BioMed Research International·Sigbjørn Berentsen, Tatjana Sundic
Jun 13, 2013·Blood·Paul L SwiecickiMorie A Gertz
Jun 28, 2014·Blood·Sigbjørn Berentsen
Dec 8, 2015·Hematology·Robert A Brodsky
Dec 23, 2016·British Journal of Haematology·Quentin A HillUNKNOWN British Society for Haematology
Apr 1, 2017·Blood·Ronald S GoNeil E Kay
Oct 28, 2017·Clinical Pediatrics·Ethan SpeirSarah Varghese
Jan 25, 2018·British Journal of Haematology·Sigbjørn Berentsen
Jun 21, 2018·Expert Review of Hematology·Tim R De BackSanne H Tonino
Sep 12, 2018·Expert Review of Clinical Immunology·Wilma BarcelliniAnna Zaninoni
Dec 7, 2018·Hematology·Anita Hill, Quentin A Hill
Oct 30, 2010·Blood·Marvin J Stone
Dec 4, 2016·Hematology·Sigbjørn Berentsen
Jul 29, 2017·Blood·Ulrich Jaeger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

© 2021 Meta ULC. All rights reserved